Immediate Impact
1 from Science/Nature 42 standout
Citing Papers
Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis
2024 Standout
Pathogenesis of autoimmune disease
2023 Standout
Works of E Özdirim being referenced
Myasthenia gravis in childhood
1996
3,4-Diaminopyridine in Childhood Myasthenia: Double-Blind, Placebo-Controlled Trial
1996
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| E Özdirim | 59 | 125 | 62 | 18 | 251 | |
| Ana Felipe‐Rucián | 51 | 219 | 67 | 18 | 287 | |
| Julien Hébert | 43 | 194 | 38 | 31 | 262 | |
| Rossella Vivarelli | 96 | 129 | 92 | 13 | 284 | |
| Yusuke Moriya | 42 | 86 | 45 | 14 | 191 | |
| Grayson Beecher | 26 | 178 | 35 | 31 | 258 | |
| Shailee Shah | 19 | 189 | 37 | 28 | 271 | |
| Eirini Apostolou | 49 | 50 | 89 | 21 | 280 | |
| Rajat Lahoria | 118 | 75 | 68 | 14 | 272 | |
| Katherine S. Elliott | 29 | 89 | 71 | 12 | 231 | |
| Alfredo Pinto | 23 | 40 | 90 | 20 | 284 |
All Works
Loading papers...